Table 1.
Clinicopathologic features of small intestinal and pancreatic neuroendocrine tumor patients with and without liver micrometastasis
| All cases (n=65) |
Pan-NET (n=22) |
SI-NET (n=43) |
P-value | No micrometastasis (n=29) |
Micrometstasis (n=36) |
P-value | ||
|---|---|---|---|---|---|---|---|---|
| Sex | Female | 39 (60%) | 17 (77%) | 22 (51%) | 0.06 | 18 (62%) | 21 (58%) | 0.80 |
| Male | 26 (40%) | 5 (23%) | 21 (49%) | 11 (38%) | 15 (42%) | |||
| Age (mean ± SD) | 57.5±12.3 | 56.8±13.7 | 57.9±11.8 | 0.74 | 57.5±12.3 | 59.8±11.4 | 0.22 | |
| Stage at diagnosis | III | 10 (15%) | 6 (27%) | 4 (9%) | 0.08 | 5 (17%) | 5 (14%) | 0.74 |
| IV | 55 (85%) | 16 (73%) | 39 (91%) | 24 (83%) | 31 (86%) | |||
| Primary tumor size (mean±SD; cm) (n=56) | 3.1±2.8 | 5.3±3.9 | 2.0±0.8 | <0.01 | 4.2±3.7 | 2.2±1.2 | <0.01 | |
| Primary tumor | Single | 44 (76%) | 17 (89 %) | 27 (69%) | 0.11 | 19 (76%) | 25 (76%) | 1.00 |
| Focality (n=58) | Multiple | 14 (24%) | 2 (11%) | 12(31%) | 6 (24%) | 8 (24%) | ||
| pT category (n=59)* | T1-2 | 9 (15%) | 6 (32%) | 3 (7%) | 0.01 | 5 (20%) | 4 (12%) | 0.10 |
| T3 | 39 (66%) | 13 (68%) | 26 (65%) | 18 (72%) | 21 (62%) | |||
| T4 | 11 (19%) | 0 | 11 (28%) | 2 (8%) | 9 (26%) | |||
| pN category (n=58) | N0 | 8 (14%) | 3 (18%) | 5 (10%) | 0.68 | 5 (21%) | 3 (9%) | 0.26 |
| N1/2 | 50 (86%) | 14 (82%) | 36 (90%) | 19 (79%) | 31 (91%) | |||
| MTD size (cm) (n=35) | 2.4±1.9 | 2.4±1.9 | 3.0±2.7 | 2.1±1.4 | 0.18 | |||
| Primary tumor LVI (n=59) | No | 5 (8%) | 5 (36%) | 0 (0%) | <0.01 | 5 (20%) | 0 (0%) | 0.01 |
| Yes | 54 (92%) | 14 (64%) | 40 (100%) | 20 (80%) | 34 (100%) | |||
| Primary tumor** WHO grade (n=58) | 1 | 37 (64%) | 5 (26%) | 32 (82%) | <0.01 | 14 (56%) | 23 (70%) | 0.41 |
| 2 | 14 (24%) | 7 (37%) | 7 (18%) | 6 (24%) | 8 (24%) | |||
| 3 | 7 (12%) | 7 (37%) | 0 (0%) | 5 (20%) | 2 (6%) | |||
| Liver lesion*** WHO grade (n=63) | 1 | 26 (41%) | 7(32%) | 19 (46%) | 0.03 | 11 (38%) | 15 (44%) | 0.87 |
| 2 | 21 (34%) | 5 (23%) | 16 (39%) | 10 (34%) | 11 (32%) | |||
| 3 | 16 (25%) | 10 (45%) | 6 (15%) | 8 (28%) | 8 (24%) | |||
| Number of liver lesions | ≤5 | 26 (40%) | 12 (54%) | 14 (33%) | 0.11 | 19 (66%) | 7 (19%) | <0.01 |
| >5 | 39 (60%) | 10 (46%) | 29 (67%) | 10 (34%) | 29 (81%) | |||
| Largest liver lesion (cm) | 2.6±2.1 | 2.7±2.8 | 2.5±1.6 | 0.69 | 1.9±0.8 | 3.1±2.6 | 0.02 | |
| Margin status | R0 | 32 (49%) | 15 (68%) | 17 (40%) | 0.04 | 19 (66%) | 13 (36%) | 0.03 |
| R1/R | 2 | 33 (51%) | 7 (32%) | 26 (60%) | 10 (34%) | 23 (64%) | ||
| Systemic treatment | No | 21 (32%) | 4 (18%) | 17 (40%) | 0.04 | 10 (34%) | 11 (31%) | 0.79 |
| Pre | 9 (14%) | 5 (23% | 4 (9%) | 6 (21%) | 3 (8%) | |||
| Post | 22 (34%) | 11 (50%) | 11 (60%) | 11(48%) | 11 (31%) | |||
| Both | 13 (20%) | 2 (9%) | 11 (26%) | 2 (7%) | 11 (31%) | |||
| Micrometast asis | Yes | 36 (55%) | 7 (32%) | 29 (67%) | 0.01 | |||
| No | 29 (45%) | 15 (68%) | 14 (33%) | |||||
PanNET: Pancreatic neuroendocrine tumor; SI-NET: small intestinal neuroendocrine tumor; MTD: mesenteric tumor deposit; LVI: lymphovascular invasion.
*
: comparing between T1–2 and T3–4;
**
: comparing WHO grade 1 and WHO grade 2–3;
***
: comparing WHO grade 1–2 and WHO grade 3.